178 related articles for article (PubMed ID: 21084039)
21. Population pharmacokinetics of tofacitinib in patients with psoriatic arthritis
.
Xie R; Deng C; Wang Q; Kanik KS; Nicholas T; Menon S
Int J Clin Pharmacol Ther; 2019 Sep; 57(9):464-473. PubMed ID: 31319908
[TBL] [Abstract][Full Text] [Related]
22. Comparison of the pharmacokinetics of subcutaneous ustekinumab between Chinese and non-Chinese healthy male subjects across two Phase 1 studies.
Zhu Y; Wang Q; Frederick B; Bouman-Thio E; Marini JC; Keen M; Petty KJ; Davis HM; Zhou H
Clin Drug Investig; 2013 Apr; 33(4):291-301. PubMed ID: 23512638
[TBL] [Abstract][Full Text] [Related]
23. Spotlight on ustekinumab in moderate to severe plaque psoriasis.
Croxtall JD
Am J Clin Dermatol; 2012 Apr; 13(2):135-7. PubMed ID: 22201419
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2).
Kavanaugh A; Puig L; Gottlieb AB; Ritchlin C; You Y; Li S; Song M; Randazzo B; Rahman P; McInnes IB
Ann Rheum Dis; 2016 Nov; 75(11):1984-1988. PubMed ID: 27098404
[TBL] [Abstract][Full Text] [Related]
25. Population pharmacokinetics of efalizumab (humanized monoclonal anti-CD11a antibody) following long-term subcutaneous weekly dosing in psoriasis subjects.
Sun YN; Lu JF; Joshi A; Compton P; Kwon P; Bruno RA
J Clin Pharmacol; 2005 Apr; 45(4):468-76. PubMed ID: 15778428
[TBL] [Abstract][Full Text] [Related]
26. A review of ustekinumab in the treatment of psoriatic arthritis.
Roberts J; O'Rielly DD; Rahman P
Immunotherapy; 2018 Apr; 10(5):361-372. PubMed ID: 29439608
[TBL] [Abstract][Full Text] [Related]
27. Population Pharmacokinetics of Risankizumab in Healthy Volunteers and Subjects with Moderate to Severe Plaque Psoriasis: Integrated Analyses of Phase I-III Clinical Trials.
Suleiman AA; Minocha M; Khatri A; Pang Y; Othman AA
Clin Pharmacokinet; 2019 Oct; 58(10):1309-1321. PubMed ID: 31054118
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study.
van Vollenhoven RF; Hahn BH; Tsokos GC; Wagner CL; Lipsky P; Touma Z; Werth VP; Gordon RM; Zhou B; Hsu B; Chevrier M; Triebel M; Jordan JL; Rose S
Lancet; 2018 Oct; 392(10155):1330-1339. PubMed ID: 30249507
[TBL] [Abstract][Full Text] [Related]
29. Efalizumab for the treatment of psoriatic arthritis.
Papp KA; Caro I; Leung HM; Garovoy M; Mease PJ
J Cutan Med Surg; 2007; 11(2):57-66. PubMed ID: 17374316
[TBL] [Abstract][Full Text] [Related]
30. Ustekinumab: The "New Kid on the Block" in the Treatment of Psoriatic Arthritis.
Torres T; Faria R
Drug Dev Res; 2015 Dec; 76(8):428-31. PubMed ID: 26372543
[TBL] [Abstract][Full Text] [Related]
31. Ustekinumab for the treatment of psoriatic arthritis.
Wofford J; Menter A
Expert Rev Clin Immunol; 2014 Feb; 10(2):189-202. PubMed ID: 24410536
[TBL] [Abstract][Full Text] [Related]
32. The Clinical and Cost Effectiveness of Ustekinumab for the Treatment of Psoriatic Arthritis: A Critique of the Evidence.
O'Connor J; Rice S; Smith A; Rodgers M; Lopez RR; Craig D; Woolacott N
Pharmacoeconomics; 2016 Apr; 34(4):337-48. PubMed ID: 26818809
[TBL] [Abstract][Full Text] [Related]
33. Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: Results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study.
Araujo EG; Englbrecht M; Hoepken S; Finzel S; Kampylafka E; Kleyer A; Bayat S; Schoenau V; Hueber A; Rech J; Schett G
Semin Arthritis Rheum; 2019 Feb; 48(4):632-637. PubMed ID: 30037432
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness and safety of ustekinumab in naïve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study.
Chimenti MS; Ortolan A; Lorenzin M; Triggianese P; Talamonti M; Costa L; Caso F; Favero M; Teoli M; Galluzzo M; Scarpa R; Punzi L; Perricone R; Ramonda R
Clin Rheumatol; 2018 Feb; 37(2):397-405. PubMed ID: 29302829
[TBL] [Abstract][Full Text] [Related]
35. Maintenance of Clinical Efficacy and Radiographic Benefit Through Two Years of Ustekinumab Therapy in Patients With Active Psoriatic Arthritis: Results From a Randomized, Placebo-Controlled Phase III Trial.
Kavanaugh A; Puig L; Gottlieb AB; Ritchlin C; Li S; Wang Y; Mendelsohn AM; Song M; Zhu Y; Rahman P; McInnes IB;
Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1739-49. PubMed ID: 26097039
[TBL] [Abstract][Full Text] [Related]
36. Ustekinumab Treatment and Improvement of Physical Function and Health-Related Quality of Life in Patients With Psoriatic Arthritis.
Rahman P; Puig L; Gottlieb AB; Kavanaugh A; McInnes IB; Ritchlin C; Li S; Wang Y; Song M; Mendelsohn A; Han C;
Arthritis Care Res (Hoboken); 2016 Dec; 68(12):1812-1822. PubMed ID: 27483458
[TBL] [Abstract][Full Text] [Related]
37. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial.
Gladman DD; Mease PJ; Ritchlin CT; Choy EH; Sharp JT; Ory PA; Perdok RJ; Sasso EH
Arthritis Rheum; 2007 Feb; 56(2):476-88. PubMed ID: 17265483
[TBL] [Abstract][Full Text] [Related]
38. Drug survival and effectiveness of ustekinumab in patients with psoriatic arthritis. Real-life data from the biologic Apulian registry (BIOPURE).
Iannone F; Santo L; Bucci R; Semeraro A; Carlino G; Paoletti F; Quarta L; Leucci P; Zuccaro C; Marsico A; Scioscia C; D'Onofrio F; Mazzotta D; Muratore M; Cantatore FP; Lapadula G
Clin Rheumatol; 2018 Mar; 37(3):667-675. PubMed ID: 29411182
[TBL] [Abstract][Full Text] [Related]
39. A novel biological target for the treatment of psoriatic arthritis.
Spadaro A; Montepaone M; Lubrano E
Immunotherapy; 2014; 6(5):515-8. PubMed ID: 24896622
[TBL] [Abstract][Full Text] [Related]
40. Integrated Population Pharmacokinetic Analysis of Ustekinumab Across Multiple Immune-Mediated Inflammatory Disease Populations and Healthy Subjects.
Shao J; Xu Z; Xu Y
Eur J Drug Metab Pharmacokinet; 2022 Jul; 47(4):537-548. PubMed ID: 35442011
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
